171 related articles for article (PubMed ID: 27267632)
1. Polyplex-mediated inhibition of chemokine receptor CXCR4 and chromatin-remodeling enzyme NCOA3 impedes pancreatic cancer progression and metastasis.
Wang Y; Kumar S; Rachagani S; Sajja BR; Xie Y; Hang Y; Jain M; Li J; Boska MD; Batra SK; Oupický D
Biomaterials; 2016 Sep; 101():108-120. PubMed ID: 27267632
[TBL] [Abstract][Full Text] [Related]
2. Reversibly Stabilized Polycation Nanoparticles for Combination Treatment of Early- and Late-Stage Metastatic Breast Cancer.
Chen G; Wang Y; Wu P; Zhou Y; Yu F; Zhu C; Li Z; Hang Y; Wang K; Li J; Sun M; Oupicky D
ACS Nano; 2018 Jul; 12(7):6620-6636. PubMed ID: 29985577
[TBL] [Abstract][Full Text] [Related]
3. NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer.
Kumar S; Das S; Rachagani S; Kaur S; Joshi S; Johansson SL; Ponnusamy MP; Jain M; Batra SK
Oncogene; 2015 Sep; 34(37):4879-89. PubMed ID: 25531332
[TBL] [Abstract][Full Text] [Related]
4. Stromal Modulation and Treatment of Metastatic Pancreatic Cancer with Local Intraperitoneal Triple miRNA/siRNA Nanotherapy.
Xie Y; Hang Y; Wang Y; Sleightholm R; Prajapati DR; Bader J; Yu A; Tang W; Jaramillo L; Li J; Singh RK; Oupický D
ACS Nano; 2020 Jan; 14(1):255-271. PubMed ID: 31927946
[TBL] [Abstract][Full Text] [Related]
5. Development of functional poly(amido amine) CXCR4 antagonists with the ability to mobilize leukocytes and deliver nucleic acids.
Wang Y; Hazeldine ST; Li J; Oupický D
Adv Healthc Mater; 2015 Apr; 4(5):729-38. PubMed ID: 25491178
[TBL] [Abstract][Full Text] [Related]
6. Honokiol suppresses pancreatic tumor growth, metastasis and desmoplasia by interfering with tumor-stromal cross-talk.
Averett C; Bhardwaj A; Arora S; Srivastava SK; Khan MA; Ahmad A; Singh S; Carter JE; Khushman M; Singh AP
Carcinogenesis; 2016 Nov; 37(11):1052-1061. PubMed ID: 27609457
[TBL] [Abstract][Full Text] [Related]
7. Use of polymeric CXCR4 inhibitors as siRNA delivery vehicles for the treatment of acute myeloid leukemia.
Wang Y; Xie Y; Williams J; Hang Y; Richter L; Becker M; Amador C; Oupický D; Hyde RK
Cancer Gene Ther; 2020 Feb; 27(1-2):45-55. PubMed ID: 31028289
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol Modification Enhances Antimetastatic Activity and siRNA Delivery Efficacy of Poly(ethylenimine)-Based CXCR4 Antagonists.
Wu P; Luo X; Wu H; Yu F; Wang K; Sun M; Oupicky D
Macromol Biosci; 2018 Nov; 18(11):e1800234. PubMed ID: 30259651
[TBL] [Abstract][Full Text] [Related]
9. Increased Survival by Pulmonary Treatment of Established Lung Metastases with Dual STAT3/CXCR4 Inhibition by siRNA Nanoemulsions.
Li Z; Chen G; Ding L; Wang Y; Zhu C; Wang K; Li J; Sun M; Oupicky D
Mol Ther; 2019 Dec; 27(12):2100-2110. PubMed ID: 31481310
[TBL] [Abstract][Full Text] [Related]
10. Cyclam-Modified PEI for Combined VEGF siRNA Silencing and CXCR4 Inhibition To Treat Metastatic Breast Cancer.
Zhou Y; Yu F; Zhang F; Chen G; Wang K; Sun M; Li J; Oupický D
Biomacromolecules; 2018 Feb; 19(2):392-401. PubMed ID: 29350899
[TBL] [Abstract][Full Text] [Related]
11. CXCR4 expression increases liver and lung metastasis in a mouse model of pancreatic cancer.
Saur D; Seidler B; Schneider G; Algül H; Beck R; Senekowitsch-Schmidtke R; Schwaiger M; Schmid RM
Gastroenterology; 2005 Oct; 129(4):1237-50. PubMed ID: 16230077
[TBL] [Abstract][Full Text] [Related]
12. Balancing polymer hydrophobicity for ligand presentation and siRNA delivery in dual function CXCR4 inhibiting polyplexes.
Wang Y; Li J; Chen Y; Oupický D
Biomater Sci; 2015 Jul; 3(7):1114-23. PubMed ID: 26146552
[TBL] [Abstract][Full Text] [Related]
13. Preferential siRNA delivery to injured kidneys for combination treatment of acute kidney injury.
Tang W; Chen Y; Jang HS; Hang Y; Jogdeo CM; Li J; Ding L; Zhang C; Yu A; Yu F; Foster KW; Padanilam BJ; Oupický D
J Control Release; 2022 Jan; 341():300-313. PubMed ID: 34826532
[TBL] [Abstract][Full Text] [Related]
14. CXCR4 knockdown by small interfering RNA abrogates breast tumor growth in vivo.
Lapteva N; Yang AG; Sanders DE; Strube RW; Chen SY
Cancer Gene Ther; 2005 Jan; 12(1):84-9. PubMed ID: 15472715
[TBL] [Abstract][Full Text] [Related]
15. Conjugate Polyplexes with Anti-Invasive Properties and Improved siRNA Delivery In Vivo.
Chen Y; Li J; Oupický D
Bioconjug Chem; 2018 Feb; 29(2):296-305. PubMed ID: 29338191
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary delivery of polyplexes for combined PAI-1 gene silencing and CXCR4 inhibition to treat lung fibrosis.
Ding L; Zhu C; Yu F; Wu P; Chen G; Ullah A; Wang K; Sun M; Li J; Oupický D
Nanomedicine; 2018 Aug; 14(6):1765-1776. PubMed ID: 29777878
[TBL] [Abstract][Full Text] [Related]
17. Targeting CXCR4/SDF-1 axis by lipopolymer complexes of siRNA in acute myeloid leukemia.
Landry B; Gül-Uludağ H; Plianwong S; Kucharski C; Zak Z; Parmar MB; Kutsch O; Jiang H; Brandwein J; Uludağ H
J Control Release; 2016 Feb; 224():8-21. PubMed ID: 26742943
[TBL] [Abstract][Full Text] [Related]
18. Hypoxia induces tumor aggressiveness and the expansion of CD133-positive cells in a hypoxia-inducible factor-1α-dependent manner in pancreatic cancer cells.
Hashimoto O; Shimizu K; Semba S; Chiba S; Ku Y; Yokozaki H; Hori Y
Pathobiology; 2011; 78(4):181-92. PubMed ID: 21778785
[TBL] [Abstract][Full Text] [Related]
19. Cholangiocarcinoma therapy with nanoparticles that combine downregulation of MicroRNA-210 with inhibition of cancer cell invasiveness.
Xie Y; Wang Y; Li J; Hang Y; Jaramillo L; Wehrkamp CJ; Phillippi MA; Mohr AM; Chen Y; Talmon GA; Mott JL; Oupický D
Theranostics; 2018; 8(16):4305-4320. PubMed ID: 30214622
[TBL] [Abstract][Full Text] [Related]
20. Tpl2 induces castration resistant prostate cancer progression and metastasis.
Lee HW; Cho HJ; Lee SJ; Song HJ; Cho HJ; Park MC; Seol HJ; Lee JI; Kim S; Lee HM; Choi HY; Nam DH; Joo KM
Int J Cancer; 2015 May; 136(9):2065-77. PubMed ID: 25274482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
